TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00437749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBT-1
Description: (50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
Study: NCT02432573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed rounds
Study: NCT03154021

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Next Science OTC Oral Rinse with Essential Oils
Description: This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: OTC Oral Rinse Control
Description: This group will receive OTC Oral Rinse Control
Study: NCT01931917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Parents and Babies Program
Description: 4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
Study: NCT02505425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Support
Description: ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual HF Care
Description: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
Study: NCT00994864

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX
Description: One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Study: NCT04818905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Helichrysum italicum infusion
Description: Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot water
Description: Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
Study: NCT01881815

Intervention type: OTHER
Intervention: Swabs
Description: There is no intervention only swabs are being used to collect wound fluid samples
Study: NCT02598037

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Test meal
Description: The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
Study: NCT01193452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Leucovorin
Description: S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin, 5-fluorouracil
Description: leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks
Study: NCT03179917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Site Radiation Therapy
Description: 30 Gy of ISRT
Study: NCT01153035

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency Ablation
Description: Breast conservation surgery followed by Radiofrequency Ablation of the cavity
Study: NCT02579031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
Study: NCT02586597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation & median nerve stimulation
Description: Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.
Study: NCT00990587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine
Description: Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
Study: NCT02487381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Study: NCT02586597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation & median nerve stimulation
Description: Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation & median nerve stimulation
Description: Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.
Study: NCT02866968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLAPS
Description: Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
Study: NCT00151567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Study: NCT03333356

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiotherapy
Description: adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
Study: NCT03212976

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phase contrast magnetic resonance imaging
Description: Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phase contrast magnetic resonance imaging
Description: Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
Study: NCT02487381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01583218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days
Study: NCT02610387

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
Study: NCT03786133

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of microbiological tests
Description: Collection and comparison of microbiological data

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of microbiological tests
Description: Collection and comparison of microbiological data
Study: NCT02149121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Description: 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study: NCT00943761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg b.i.d.
Description: Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg b.i.d.
Description: Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
Study: NCT01911468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Study: NCT02063919

Intervention type: OTHER
Intervention: the mucosal microbiome in the biopsy specimen was analysed
Study: NCT01911468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and liraglutide
Study: NCT02338388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section technique
Description: Comparing three different types of suturing the uterus at Cesarea section
Study: NCT04528797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study: NCT02338388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section technique
Description: Comparing three different types of suturing the uterus at Cesarea section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section technique
Description: Comparing three different types of suturing the uterus at Cesarea section
Study: NCT00693888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
Description: initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
Study: NCT01342926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: GSK933776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: GSK933776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: GSK933776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01337778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care for Daughters-in-Law
Description: Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dil Mil Intervention
Description: The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
Study: NCT03382912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab Alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Alone
Study: NCT04528797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study: NCT02637726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TCI Schnider
Description: Target controlled infusion using schnider model for propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TCI Kataria
Description: Target controlled infusion using Kataria model for propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TIVA
Description: Total intravenous anesthesia without use of a pharmokinetic model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TIVA
Description: Total intravenous anesthesia without use of a pharmokinetic model

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Monitoring
Description: Maintaining a bispectral index between 45 and 55
Study: NCT00707473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Undergo chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgical Resection
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT02637726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Monitoring
Description: Maintaining a bispectral index between 45 and 55

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Monitoring
Description: Maintaining a bispectral index between 45 and 55

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil at discretion of the anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil at discretion of the anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil at discretion of the anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil at discretion of the anesthesiologist
Study: NCT02165033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Procaterol 180/10 X 4 puffs
Description: Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
Study: NCT00151567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Study: NCT03681522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block
Description: Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
Study: NCT01782170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01579370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quaternary ammonium
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.
Study: NCT02702011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin medium dose
Study: NCT01579370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quaternary ammonium and UV-C light
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
Study: NCT00707473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT01579370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach and UV-C light
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
Study: NCT04498663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion- and Relationship-Focused Therapeutic Interview
Description: In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.